BCL2L11: A Drug Target / Disease Biomarker (G10018)

Target Name: BCL2L11

NCBI ID: G10018

BCL2L11

BCL2L11: A Drug Target / Disease Biomarker

BCL2L11 is a protein that is expressed in a variety of tissues throughout the body, including the brain, lungs, heart, and gastrointestinal tract. It is a member of the BCL2 family of proteins, which are known for their role in regulating cell death and cell proliferation. BCL2L11 has been identified as a potential drug target due to its involvement in a variety of cellular processes that are associated with disease, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most significant functions of BCL2L11 is its role in cell death. When a cell is damaged or faces an unavoidable stressor, it can trigger a process of cell death known as apoptosis. BCL2L11 is involved in the regulation of this process, and it has been shown to play a positive role in preventing apoptosis. This is important because uncontrolled cell death can contribute to a variety of diseases, including cancer, neurodegenerative diseases, and heart disease.

Another function of BCL2L11 is its role in cell proliferation. BCL2L11 has been shown to promote the growth and proliferation of a variety of cell types, including cancer cells. This is important because uncontrolled cell proliferation can contribute to the development and progression of cancer. BCL2L11 has also been shown to play a positive role in the regulation of cell cycle progression, which is important for the development and progression of cancer.

In addition to its role in cell death and proliferation, BCL2L11 is also involved in a variety of other cellular processes that are important for normal cellular function. For example, BCL2L11 has been shown to play a positive role in the regulation of inflammation, which is important for maintaining the immune system and protecting the body against infection. BCL2L11 has also been shown to play a positive role in the regulation of cell signaling pathways, which are important for the development and progression of many diseases.

Given its involvement in a variety of cellular processes, BCL2L11 is an attractive target for drug development. By inhibiting the activity of BCL2L11, researchers can potentially reduce the development and progression of a variety of diseases. This is an important area of research because many diseases are caused by the uncontrolled regulation of cell death and proliferation. By targeting BCL2L11 with drugs, researchers can potentially develop new treatments for a variety of diseases.

Protein Name: BCL2 Like 11

Functions: Induces apoptosis and anoikis. Isoform BimL is more potent than isoform BimEL. Isoform Bim-alpha1, isoform Bim-alpha2 and isoform Bim-alpha3 induce apoptosis, although less potent than isoform BimEL, isoform BimL and isoform BimS. Isoform Bim-gamma induces apoptosis. Isoform Bim-alpha3 induces apoptosis possibly through a caspase-mediated pathway. Isoform BimAC and isoform BimABC lack the ability to induce apoptosis

The "BCL2L11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCL2L11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets